Reviewing Accelerate Diagnostics (AXDX) & IRIDEX (IRIX)

Accelerate Diagnostics (NASDAQ: AXDX) and IRIDEX (NASDAQ:IRIX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings.

Earnings & Valuation

This table compares Accelerate Diagnostics and IRIDEX’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Accelerate Diagnostics $250,000.00 6,005.36 -$66.37 million ($1.20) -22.58
IRIDEX $46.16 million 1.99 -$11.71 million ($1.71) -4.65

IRIDEX has higher revenue and earnings than Accelerate Diagnostics. Accelerate Diagnostics is trading at a lower price-to-earnings ratio than IRIDEX, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Accelerate Diagnostics and IRIDEX, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Accelerate Diagnostics 0 0 2 0 3.00
IRIDEX 0 0 1 0 3.00

Accelerate Diagnostics currently has a consensus target price of $33.00, suggesting a potential upside of 21.77%. IRIDEX has a consensus target price of $13.00, suggesting a potential upside of 63.52%. Given IRIDEX’s higher possible upside, analysts plainly believe IRIDEX is more favorable than Accelerate Diagnostics.

Risk and Volatility

Accelerate Diagnostics has a beta of 2.17, suggesting that its share price is 117% more volatile than the S&P 500. Comparatively, IRIDEX has a beta of 1.31, suggesting that its share price is 31% more volatile than the S&P 500.

Insider and Institutional Ownership

48.0% of Accelerate Diagnostics shares are held by institutional investors. Comparatively, 49.3% of IRIDEX shares are held by institutional investors. 50.0% of Accelerate Diagnostics shares are held by company insiders. Comparatively, 5.0% of IRIDEX shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Accelerate Diagnostics and IRIDEX’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Accelerate Diagnostics -3,085.36% -60.99% -57.85%
IRIDEX -42.22% -23.21% -19.03%

Summary

IRIDEX beats Accelerate Diagnostics on 7 of the 12 factors compared between the two stocks.

About Accelerate Diagnostics

Accelerate Diagnostics, Inc. is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company’s in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. It detects and identifies pathogens directly from a single patient sample followed by antimicrobial susceptibility testing based on the identification results. The Accelerate PhenoTest BC Kit provides ID and AST results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The Accelerate Pheno system features walk-away automation and consists of a fixed instrument and single-use test kit.

About IRIDEX

IRIDEX Corporation is a provider of therapeutic based laser consoles, delivery devices and consumable instrumentation used to treat sight-threatening eye diseases in ophthalmology. The Company operates through ophthalmology segment. Its ophthalmology products consist of laser consoles, delivery devices and consumable instrumentation, including laser probes, and are used in the treatment of serious eye diseases, including the over three causes of irreversible blindness, such as diabetic retinopathy, glaucoma and age-related macular degeneration (AMD). In addition, the Company’s ophthalmology products are often used in vitrectomy procedures (used to treat proliferative diabetic retinopathy, macular holes, retinal tears and detachments), which are generally performed in the operating room and require a consumable single use intraocular laser probe (EndoProbe) to deliver light to the back of the eye together with other instrumentation.

What are top analysts saying about Accelerate Diagnostics Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Accelerate Diagnostics Inc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit